Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...